| 000 | 01692 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514214059.0 | ||
| 264 | 0 | _c20050825 | |
| 008 | 200508s 0 0 eng d | ||
| 022 | _a0885-3185 | ||
| 024 | 7 |
_a10.1002/mds.20381 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRacette, Brad A | |
| 245 | 0 | 0 |
_a[18F]FDOPA PET and clinical features in parkinsonism due to manganism. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cApr 2005 |
||
| 300 |
_a492-496 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 |
_aCarbidopa _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorodeoxyglucose F18 |
| 650 | 0 | 4 | _aGait |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xtherapeutic use |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 |
_aManganese Poisoning _xblood |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aPositron-Emission Tomography |
| 650 | 0 | 4 | _aRadiopharmaceuticals |
| 700 | 1 | _aAntenor, Jo Ann | |
| 700 | 1 | _aMcGee-Minnich, Lori | |
| 700 | 1 | _aMoerlein, Stephen M | |
| 700 | 1 | _aVideen, Tom O | |
| 700 | 1 | _aKotagal, Vikas | |
| 700 | 1 | _aPerlmutter, Joel S | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 20 _gno. 4 _gp. 492-496 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.20381 _zAvailable from publisher's website |
| 999 |
_c15327485 _d15327485 |
||